Evidence map›Paper›PMID 31227742›Full record

ArticleScientific reports2019

Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH.

Jonathan D Roth, Sanne S Veidal, Louise K D Fensholdt, Kristoffer T G Rigbolt, Romeo Papazyan, Jens Christian Nielsen, Michael Feigh, Niels Vrang, Mark Young, Jacob Jelsing and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 51 citations in OpenAlex.

  1. CD38 Inhibition Enhances FXR Signaling in Male Rats With Diabetic Steatohepatitis Through SIRT1-Dependent Suppression of NLRP3.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Therapeutic Strategies for MASH: An Update on Drug Candidates Under Investigation in Late-Phase Clinical Trials.International journal of translational medicine (Basel, Switzerland) · 2025
    Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Current investigations for liver fibrosis treatment: between repurposing the FDA-approved drugs and the other emerging approaches.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2023
    Review
  12. Review
  13. Intestinal farnesoid X receptor signaling controls hepatic fatty acid oxidation.Biochimica et biophysica acta. Molecular and cell biology of lipids · 2022
    Article
  14. Review
  15. Review
  16. New Drugs for Hepatic Fibrosis.Frontiers in pharmacology · 2022
    Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Jonathan D RothIntercept Pharmaceuticals, San Diego, CA, USA.
Sanne S VeidalGubra, Hørsholm, Denmark.
Louise K D FensholdtGubra, Hørsholm, Denmark.
Kristoffer T G RigboltGubra, Hørsholm, Denmark.
Romeo PapazyanIntercept Pharmaceuticals, San Diego, CA, USA.
Jens Christian NielsenGubra, Hørsholm, Denmark.
Michael FeighGubra, Hørsholm, Denmark.
Niels VrangGubra, Hørsholm, Denmark.
Mark YoungIntercept Pharmaceuticals, San Diego, CA, USA.
Jacob JelsingGubra, Hørsholm, Denmark.
Luciano AdoriniIntercept Pharmaceuticals, San Diego, CA, USA.
Henrik H HansenGubra, Hørsholm, Denmark. hbh@gubra.dk.ORCID http://orcid.org/0000-0002-3732-0281
Gubra (Denmark) · DKIntercept Pharmaceuticals (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Obeticholic acid (OCA) and elafibranor (ELA) are selective and potent agonists for the farnesoid X receptor (FXR) and dual peroxisome proliferator-activated receptor α/δ (PPAR-α/δ), respectively. Both agents have demonstrated clinical efficacy in nonalcoholic steatohepatitis (NASH). The present study used OCA and ELA to compare the effects of mono- and combination therapies on metabolic and histological endpoints in Lep

Indexed as

AnimalsBiopsyChalconesChenodeoxycholic AcidDisease Models, AnimalLiver CirrhosisMicePPAR alphaProof of Concept StudyPropionatesTranscription, Genetic2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic acidChalconesChenodeoxycholic Acidobeticholic acidPPAR alphaPropionates

Identifiers

PMID31227742
PMCPMC6588626
OpenAlexW2950655372

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.